Medicare Enrolled

Dr. Kateryna Komarovskiy, MD

Endocrinology · Shenandoah, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
150 PINE FOREST DR, Shenandoah, TX 77384
9367554238
In practice since 2008 (17 years)
NPI: 1265694285 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Komarovskiy from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Komarovskiy? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Komarovskiy

Dr. Kateryna Komarovskiy is an endocrinology in Shenandoah, TX, with 17 years in practice. Based on federal Medicare data, Dr. Komarovskiy performed 8,483 Medicare services across 1,248 unique beneficiaries.

Between the years covered by Open Payments, Dr. Komarovskiy received a total of $18,062 from 54 pharmaceutical and/or device companies across 812 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in endocrinology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Komarovskiy is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 17 years in practice▲ Top 5% volume in TX$ $18,062 industry payments

Medicare Practice Summary

Medicare Utilization ↗
8,483
Medicare services
Top 5% in TX for endocrinology
1,248
Unique beneficiaries
$25
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~499 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Denosumab injection (Prolia/Xgeva)5,970$19$28
Office visit, established patient (30-39 min)852$84$208
Hemoglobin A1c test (diabetes monitoring)691$9$36
Blood glucose (sugar) level430$4$15
Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report245$26$86
Lipid panel (cholesterol and triglycerides)105$13$70
Drug injection, under skin or into muscle99$10$48
Office visit, established patient, complex (40-54 min)56$127$282
New patient office visit (45-59 min)35$102$320
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$18,062
Total received (2018-2024)
Avg $2,580/year across 7 years
Top 24% in TX for endocrinology
54
Companies
812
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$16,153 (89.4%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$1,909 (10.6%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$2,288
2023
$1,831
2022
$2,945
2021
$2,113
2020
$1,220
2019
$4,452
2018
$3,212

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Novo Nordisk Inc
$2,617
AstraZeneca Pharmaceuticals LP
$1,613
Lilly USA, LLC
$1,224
SANOFI-AVENTIS U.S. LLC
$1,217
Amgen Inc.
$1,183
Corcept Therapeutics
$1,094
Boehringer Ingelheim Pharmaceuticals, Inc.
$832
Radius Health, Inc.
$748
Insulet Corporation
$724
Valeritas, Inc.
$510
Medtronic MiniMed, Inc.
$506
Dexcom, Inc.
$413
Tandem Diabetes Care, Inc.
$399
Xeris Pharmaceuticals, Inc.
$394
Companion Medical, Inc.
$331
Abbott Laboratories
$300
IBSA Pharma Inc.
$295
Novartis Pharmaceuticals Corporation
$269
Bayer Healthcare Pharmaceuticals Inc.
$244
Aytu BioScience, Inc
$243
Merck Sharp & Dohme Corporation
$235
Amneal Pharmaceuticals LLC
$208
Amarin Pharma Inc.
$195
MannKind Corporation
$191
Bigfoot Biomedical Inc
$180
Janssen Pharmaceuticals, Inc
$153
Mannkind Corporation
$152
BETA BIONICS, INC.
$137
Antares Pharma, Inc.
$130
Shire North American Group Inc
$122
Becton, Dickinson and Company
$121
Esperion Therapeutics, Inc.
$104
Zealand Pharma US, Inc.
$99
Medtronic, Inc.
$92
AbbVie Inc.
$75
Verity Pharmaceuticals Inc.
$73
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$70
ABBVIE INC.
$65
Tolmar, Inc.
$64
Clarus Therapeutics Inc.
$58
Amphastar Pharmaceuticals, Inc.
$54
Endo Pharmaceuticals Inc.
$52
Acerus Pharmaceuticals Corporation
$50
Currax Pharmaceuticals LLC
$28
Nestle HealthCare Nutrition Inc.
$24
Alexion Pharmaceuticals, Inc.
$23
Astellas Pharma US Inc
$22
VIVUS LLC
$21
LifeScan, Inc.
$19
Intuity Medical Inc
$19
Kowa Pharmaceuticals America, Inc.
$19
CeQur Corporation
$18
KVK-Tech, Inc.
$16
Merck Sharp & Dohme LLC
$16
Top 3 companies account for 30.2% of total payments
Associated products mentioned in payments ›
AFREZZA · Aimovig · BAQSIMI · BASAGLAR · BD Nano · BD Nano 2nd Gen Pen Needle · BYDUREON · CONTRAVE · CREON · CYCLOSET · CeQur Simplicity · DEXCOM CGM · DEXCOM G6 CGM SYSTEM · DIABETES - DISEASE · Dexcom G6 Transmitter · ENTRESTO · EVENITY · FARXIGA · FORTEO · FREESTYLE LIBRE · FREESTYLE LIBRE 2 · FREESTYLE LIBRE 3 · FreeStyle Libre · FreeStyle Libre 2 · FreeStyle Libre blood glucose Flash Monitoring System · GLUCAGON · GVOKE HYPOPEN · GVOKE PFS · HUMULIN · HUMULIN R 500 · INPEN SMART INSULIN DELIVERY SYSTEM · INTELLIS ADAPTIVESTIM · INVOKANA · InPen · JANUVIA · JARDIANCE · JATENZO · Kerendia · Korlym · LEQVIO · LICART · LINZESS · LOKELMA · LYUMJEV · Livalo · MINIMED 780G · MOUNJARO · Minimed 630G · Minimed 670G System · NASCOBAL · NATPARA · NATPARA (PARATHYROID HORMONE) · NEXLETOL · NOCDURNA · Natesto · OTREXUP · Omnipod · OneTouch · Otrexup · Ozempic · PANCREAZE · Pogo Automatic Blood Glucose Monitoring System · Prolia · RECORLEV · RYBELSUS · Repatha · Rybelsus · SOLIQUA · SOLIQUA 100/33 · STEGLUJAN · SYNTHROID · Saxenda · Strensiq · TOUJEO · TRULICITY · TZIELD · Tirosint · Tlando · Tresiba · Tymlos · UBRELVY · UNITHROID · UNITY DIABETES MANAGEMENT SYSTEM · V-GO · V-GO DISPOSABLE INSULIN DELIVERY · Vascepa · Veozah · Victoza · Wegovy · XARELTO · XYOSTED · ZEGALOGUE · ZENPEP · ZEPBOUND · iLet Bionic Pancreas · t-slim insulin pump · t:slim X2 Insulin Pump with Control-IQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (89%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $213 per 100 Medicare services performed
Looking for a endocrinology in Shenandoah?
Compare endocrinologys in the Shenandoah area by procedure volume, costs, and industry payment transparency.
Browse endocrinologys nearby

Geographic Context

Endocrinologys within 10 mi
28
Per 100K population
4.3
County median income
$97,266
Nearest hospital
ST LUKE'S THE WOODLANDS HOSPITAL
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Komarovskiy is a mixed practice specialist, with above-average Medicare volume (top 5% in TX), and low-engagement industry engagement, with 17 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Komarovskiy experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Komarovskiy performed 5,970 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Komarovskiy receive payments from pharmaceutical companies?
Yes. Dr. Komarovskiy received a total of $18,062 from 54 companies across 812 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Komarovskiy's costs compare to other endocrinologys in Shenandoah?
Dr. Komarovskiy's average Medicare payment per service is $25. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Komarovskiy) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →